

DAFTAR PUSTAKA

- Agustina, F. A. (2010). *Analisis Hubungan Faktor-Faktir Yang Menentukan Kesembuhan Penderita Kusta (Studi Kasus di Puskesmas Kunduran dan di Puskesmas Banjarejo Kabupaten Blora)*. Universitas Diponegoro.
- Ama, P. G. B. (2018). Ketidakteraturan Minum Obat MDT Pada Penderita Kusta di Rumah Sakit Kusta Dr. Sitanala, Tangerang-Banten. *Jurnal Ilmiah Kesehatan, 10*(1), 110–118.
- B. Kumar, S. Uprety, S. D. (2017). *Clinical diagnosis of Leprosy*. <https://doi.org/10.1097/AAP.0000000000000317>
- Bokhary, M., & Phung, T. L. (2017). Molecular Pathogenesis of Leprosy. *Current Tropical Medicine Reports*, (December). <https://doi.org/10.1007/s40475-016-0094-y>
- Brennan, P. J., & Spencer, J. S. (2019). *The Physiology of Mycobacterium leprae Morphology and Cell Wall*.
- Cambau, E., & Williams, D. L. (2019). Anti-Leprosy Drugs : Modes of Action and Mechanisms of Resistance in Mycobacterium leprae Mode of Action and Antibacterial Activity. In *The International Textbook of Leprosy* (pp. 1–33).
- Da Silva Junior, G. B., De Francesco Daher, E., Da Justa Pires Neto, R., Pereira, E. D. B., Meneses, G. C., AraÚJo, S. M. H. A., & Barros, E. J. G. (2015). Leprosy nephropathy: A review of clinical and histopathological features. *Revista Do Instituto de Medicina Tropical de Sao Paulo, 57*(1), 15–20. <https://doi.org/10.1590/S0036-46652015000100002>
- Delfina, M., Wandita, S., & Laksanawati, I. S. (2017). *Faktor Risiko Anemia pada Pasien Kusta Anak dalam terapi MDT*. 18(5), 363–367.
- Fischer, M. (2017). *Leprosy – an overview of clinical features , diagnosis , and treatment*. 801–827. <https://doi.org/10.1111/ddg.13301>
- Gardiner, B. J. (2016). *Comorbidities in Patients with Hansen ' s Disease*. 2014(1), 1–18.
- Guragain, S., Upadhayay, N., & Bhattarai, B. M. (2017). Adverse reactions in leprosy patients who underwent dapsone multidrug therapy : a retrospective study. *Dove Press Joournal, 73–78*.
- Kamal, M., & Martini, S. (2015). Kurangnya Konseling dan Penemuan Kasus Secara Pasif Mempengaruhi Kejadian Kecacatan Tingkat II di Kabupaten Sampang. *Jurnal Berkala Epidemiologi, 3*(3).
- Kar, S., Pal, R., & Bharati, D. R. (2019). *Understanding non-compliance with WHO- multidrug therapy among leprosy patients in*. 1(1), 9–13. <https://doi.org/10.4103/0976-3147.63093>

- Katzung, B. G., Masters, S. B., & Trevor, A. J. (2012). *Farmakologi Dasar dan Klinik* (R. Soeharsono, Ed.).
- Kementerian Kesehatan Republik Indonesia. (2018a). *Data dan Informasi Profil Kesehatan Indonesia*.
- Kementerian Kesehatan Republik Indonesia. (2018b). *Hapuskan Stigma dan Diskriminasi Terhadap Kusta*.
- Khofifah, B., & Gayatri, D. (2014). *Distribusi Spasial Kasus Kusta di Tiga Wilayah Kerja Puskesmas Kabupaten Lamongan , Jawa Timur Tahun 2012*.
- Lechat, M. F. (2016). Epidemiology of leprosy. In *Quaderni di Cooperazione Sanitaria*.
- Lockwood, D. N. J. (2019). *Treatment of Leprosy*. Retrieved from <http://www.internationaltextbookofleprosy.org/>
- Lockwood, D. N. J., Nicholls, P., Smith, W. C. S., Das, L., Barkataki, P., van Brakel, W., & Suneetha, S. (2012). Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the infir cohort of indian patients with multibacillary leprosy. *PLoS Neglected Tropical Diseases*, 6(6). <https://doi.org/10.1371/journal.pntd.0001702>
- Luna, R. (2015). *Hubungan Kinerja Pengawas Minum Obat (PMO) Terhadap Kepatuhan Minum Obat Pada Penderita Kusta di Wilayah Kerja Puskesmas Kedungkandang Kota Malang*. Universitas Muhammadiyah Malang.
- M. Hadi & M. Kumalasari. (2017). *Kusta Stadium Subklinis* (F. Andiana, Ed.). Surabaya.
- Mahendra, N., Yaduvanshi, R., Sharma, C. S., Ali, R., Rathore, P. K., & Kuchhal, A. (2018). Psychiatry Psychiatric Co-morbidity in Patients of Hansen ' s Disease. *International Journal of Contemporary Research*, 5(1), 1–5.
- Menteri Kesehatan Republik Indonesia. (2019). *Penanggulangan Kusta*. Jakarta.
- Mieras, L. F., Taal, A. T., van Brakel, W. H., Cambau, E., Saunderson, P. R., Smith, W. C. S., ... Sturkenboom, M. G. G. (2018). An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++. *BMC Infectious Diseases*, 18(1), 1–8. <https://doi.org/10.1186/s12879-018-3402-4>
- Mudatsir, M. (2019). *Faktor-Faktor yang Mempengaruhi Terjadinya Infeksi Kusta*. (August 2010).
- Muntasir, M., Salju, E. V., & Rulianti, L. P. (2018). Studi Faktor-Faktor Yang Berhubungan Dengan Kejadian Penyakit Kusta Pada Wilayah Kerja Puskesmas Bakunase Kota Kupang Tahun 2017. *Jurnal Info Kesehatan*, 16(2), 197–213. <https://doi.org/10.31965/infokes.vol16.iss2.223>
- Paul, M. S. K., & Kumar, D. P. (2019). Physical Rehabilitation in Leprosy. In *The International Textbook of Leprosy* (pp. 1–42).

- Putu, L., & Gusti, S. I. (2018). *Prevalensi dan Karakteristik Penderita Reaksi Kusta Tipe 1 di Poliklinik Kulit dan Kelamin RSUP Sanglah*. 7(11), 1–5.
- Richardus, J. H., Pahan, D., Johnson, R. C., & Foundation, R. F. (2016). *Leprosy Control*. Retrieved from <http://www.internationaltextbookofleprosy.org/>
- Scollard, D. M. (2016). *Pathogenesis and pathology of leprosy*. Retrieved from <https://www.internationaltextbookofleprosy.org/chapter/pathology?sect=authors>
- Sharma, P., & Al., E. (1996). *Disabilities in Multibacillary leprosy patient : before, during, and after multidrug therapy*.
- Tami, M. (2019). *Faktor Risiko Kejadian Kecacatan Tingkat II Pada Penderita Kusta*. Universitas Airlangga.
- Team Medical Mini Notes. (2017). *Basic Pharmacy & Drug Notes*. Makasar: MMN Publishing.
- Verma, A., Singh, A., Prakash, V., Bhatia, A., & Kant, S. (2015). Coexistence of leprosy and pulmonary tuberculosis: An uncommon entity. *Medical Journal of Dr. D.Y. Patil University*, 8(5), 675. <https://doi.org/10.4103/0975-2870.164954>
- WHO. (2013). *Frequently asked question on leprosy*. Retrieved from http://apps.searo.who.int/PDS_DOCS/B5044.pdf
- WHO. (2018). Leprosy(Hansen's disease). Retrieved November 5, 2019, from www.who.int/health-topics/leprosy
- Widoyono. (2011). *Penyakit Tropis*. Jakarta: Penerbit Erlangga.
- Zakiyyah, N. R., Budiono, I., & Zainafree, I. (2015). Unnes Journal of Public Health. *Unnes Journal of Public Health*, 2(3), 58–66.